Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The medicine is now approved for eight indications across five different types of cancer in China.
Subscribe To Our Newsletter & Stay Updated
